Table 2.

Patient’s characteristics and mortality in univariable analysis stratified by study. Hazard ratios for death with 95% confidence intervals for different time points are shown (study population n = 3395; n = 3362 for injection drug use, and n = 3369 for diabetes mellitus due to missing values).

	7-day mortality		14-day mortality		30-day mortality		90-day mortality
	Hazard ratio (95% CI)	p-Value	Hazard ratio (95% CI)	p-Value	Hazard ratio (95% CI)	p-Value	Hazard ratio (95% CI)	p-Value
Age at onset	1.03 (1.03–1.04)	<.0001	1.03 (1.03–1.04)	<.0001	1.03 (1.03–1.04)	<.0001	1.03 (1.03–1.04)	<.0001
Male gender	0.81 (0.65–1.02)	0.07	0.90 (0.75–1.08)	0.27	0.96 (0.83–1.12)	0.62	1.01 (0.88–1.15)	0.92
MRSA	1.59 (1.23–2.06)	0.0004	1.43 (1.16–1.76)	0.001	1.46 (1.22–1.74)	<.0001	1.61 (1.38–1.87)	<.0001
Nosocomial SAB	0.96 (0.76–1.21)	0.74	1.10 (0.92–1.33)	0.29	1.12 (0.97–1.31)	0.13	1.16 (1.02–1.32)	0.03
Injection drug use	0.72 (0.42–1.23)	0.23	0.52 (0.31–0.85)	0.009	0.55 (0.36–0.83)	0.004	0.53 (0.37–0.76)	0.0005
Diabetes mellitus	1.08 (0.84–1.39)	0.56	1.05 (0.86–1.29)	0.63	1.14 (0.97–1.35)	0.12	1.08 (0.94–1.25)	0.29
Dominant focusa
Peripheral venous catheter	0.89 (0.45–1.76)	0.74	1.06 (0.62–1.83)	0.83	1.20 (0.81–1.78)	0.37	1.10 (0.80–1.52)	0.56
Skin and soft tissue infection	1.15 (0.68–1.96)	0.60	1.49 (0.97–2.27)	0.07	1.38 (0.99–1.93)	0.05	1.30 (0.99–1.70)	0.06
Endocarditis	2.25 (1.32–3.83)	0.003	3.11 (2.04–4.74)	<.0001	3.09 (2.24–4.27)	<.0001	2.70 (2.07–3.53)	<.0001
Osteoarticular infection	0.84 (0.46–1.54)	0.57	1.07 (0.67–1.73)	0.77	1.27 (0.90–1.80)	0.17	1.24 (0.94–1.64)	0.12
Pneumonia	6.51 (4.04–10.49)	<0.0001	7.08 (4.74–10.56)	<0.0001	5.38 (3.87–7.48)	<0.0001	4.66 (3.53–6.16)	<.0001
Other focus	1.75 (1.05–2.92)	0.03	2.23 (1.48–3.37)	0.0001	1.82 (1.30–2.53)	0.0004	1.68 (1.28–2.20)	0.0002
Focus not identified	5.17 (3.44–7.77)	<.0001	5.59 (3.96–7.89)	<.0001	4.27 (3.25–5.60)	<.0001	3.45 (2.76–4.31)	<.0001

^aReference focus: central venous catheter.